From the Wires
Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board
Endometrial Stem Cell Company Expands Clinical Applications of Its Universal Donor Stem Cell Product
By: Marketwired .
Nov. 19, 2012 03:27 PM
SAN DIEGO, CA -- (Marketwire) -- 11/19/12 -- Medistem (PINKSHEETS: MEDS) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board. Dr. Gershman is an internationally-renowned opinion leader in urological surgery having pioneered numerous minimally invasive procedures using laparoscopic techniques.
"The future of regenerative medicine lies not only in having the best stem cell product, but also being able to practically deliver it in a manner that can be integrated into existing medical practice," said Dr. Alan Lewis, CEO of Medistem. "Through working with respected physicians such as Dr. Gershman, our aim is to develop novel delivery methods so that our cellular product can be utilized in numerous disciplines."
Medistem is currently running a Phase II clinical trial in heart failure patients using its Endometrial Regenerative Cell (ERC) product delivered through a 30-minute minimally invasive patent pending procedure. The company seeks to develop similar minimally invasive procedures for the field of urology in collaboration with Dr. Gershman.
"It is obvious that stem cell medicine is the future of medicine. Although great strides have occurred in clinical entry of stem cells, a major hurdle to commercialization is practical implementation," said Dr. Gershman. "I commend Medistem for having discovered what appears to be the most potent blood vessel generating stem cell, the ERC, as well as having the foresight to think practically about optimum methods of delivery."
Dr. Gershman is one of the first surgeons in the world to apply the method of laparoscopic surgery and robotic-assisted surgery to urology. He currently holds numerous hospital appointments, including the following: Director of Institute of Advanced Urology at the Cedars-Sinai Medical Center; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center; Head of Endourology Division, Department of Surgery, VA Greater Los Angeles Healthcare System; Attending Surgeon, Laparoscopic Renal Transplant Surgery, St. Mary Medical Center; Attending Surgeon at the Cedars-Sinai Medical Center; and Attending Surgeon at the Harbor-UCLA Medical Center.
ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week